" class="no-js "lang="en-US"> Morgane Rousselot - Medtech Alert
Friday, September 05, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Morgane Rousselot

Morgane Rousselot

About Morgane Rousselot

Chemical engineer, co-founder of the biotech firms HEMARINA (blood substitutes) and TOLERYS (inactivated mycobacteria). Dr. Rousselot has more than 15 years of experience in the development of active ingredients.

Related Story

Company Releases

 Seabelife Receives Close to €1.4m Deep Tech Financing From Bpifrance | Pharmtech Focus

Seabelife Receives Close to €1.4m Deep Tech Financing from Bpifrance

March 14 2022

SeaBeLife, a biotech company developing drug candidates intended to block cell necrosis, today announces that […]